Nearly a year after his SPAC combines with EQRx, Eli Casdin resigns from board
About 11 months after his investment firm’s blank check company helped boost EQRx’s cash coffers by about $1.3 billion, Eli Casdin is out from the biotech’s board.
The day before Thanksgiving, he told EQRx’s board that he would resign at the end of that day, according to an SEC filing. The decision “was not due to any disagreement with EQRx” relating to the company’s “operations, policies or practices,” as the biotech outlined in the paperwork with the agency.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.